VANCOUVER, June 6 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V:PRX) today
announced that it has completed recruitment of patients for its Phase I study
of PRX302 to treat localized, recurrent prostate cancer. The Company is on
track to report top line data from this study by mid year.